---
title: "Place- and cause-specific aggregation hides COVID-19 excess mortality patterns"
id: "medrxiv-2-aggregation-of-mortality-data-by-place-and-cause-mask-underlying-trends-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-aggregation-of-mortality-data-by-place-and-cause-mask-underlying-trends-in"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1?rss=1"
published_at: "2026-09-08T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Place- and cause-specific aggregation hides COVID-19 excess mortality patterns
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-aggregation-of-mortality-data-by-place-and-cause-mask-underlying-trends-in
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1?rss=1)
- **Published At:** 2026-09-08T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Aggregating deaths by broad cause or by larger spatial units can obscure true patterns of pandemic mortality; the authors analyzed Michigan mortality data to compare aggregated and disaggregated approaches. - Baseline expected mortality was estimated using negative binomial regression on deaths from January 2015–November 2019; observed deaths from December 2019–November 2022 were compared to these expectations. - Analyses partitioned the pandemic into seven periods defined by dominant viral strains and interventions, and aggregated deaths by cause and place (county and census tract). - Cause categories were simplified into **acute respiratory infections (ARI)** and non-ARI (all other causes) to examine cause-specific excess mortality alongside **all-cause excess mortality**. - Peak ARI excess mortality occurred in the first pandemic phase with an observed-to-expected ratio reported as 10.7; the 95% credible interval reported in the source was unclear. - By contrast, **all-cause excess mortality** rose modestly (1.20 observed-to-expected; 95% CrI: 1.17–1.22) and non-ARI excess mortality remained essentially unchanged. - County-level ARI excess mortality estimates differed substantially and unpredictably from census-tract estimates, with county values ranging from 0.42 to 1.2 times tract estimates; non-ARI and all-cause ratios were more consistent across spatial scales. - Within-county variation in ARI mortality decreased during the pandemic’s acute phases and gradually returned toward pre-pandemic levels, indicating more spatially uniform ARI mortality when rates rose statewide. - Higher social vulnerability at the census-tract level was associated with increased ARI excess mortality in the first pandemic phase (EMRR 1.1; 95% CrI: 1.08–1.13), but this association weakened when using all-cause mortality or when aggregating to the county level. - The authors conclude that relying on county-level **all-cause excess mortality** can mask important cause-specific and local patterns and that even simple disaggregation (ARI vs non-ARI) and finer spatial units (census tract) improve detection of shifts and social associations.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=90BbmjjzCm3d6hWh66DRILv1D7Nqm1JT0PcLoCSuVzc-1788887668.5484154-1.2.1.1-cntdwKN0H4gUTffi.H2qc.nfmgeL165ct5079sNydlxwEV0UEVOW1_U78.S._0_i) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Aggregation of mortality data by place and cause mask underlying trends in COVID-19 excess mortality [ View ORCID Profile](http://orcid.org/0000-0002-2220-4026)Kelly Herdzik, [ View ORCID Profile](http://orcid.org/0000-0001-7587-355X)Krzysztof Sakrejda, [ View ORCID Profile](http://orcid.org/0000-0003-4691-7802)Abram Wagner, [ View ORCID Profile](http://orcid.org/0000-0002-0708-2008)Jon Zelner doi: https://doi.org/10.64898/2026.09.04.26362260 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Kelly Herdzik 1 Amsterdam University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kelly%2BHerdzik%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Herdzik%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKelly%2BHerdzik%2B) * [ORCID record for Kelly Herdzik](http://orcid.org/0000-0002-2220-4026 "Open in new tab") * For correspondence: broenkelly@gmail.com Krzysztof Sakrejda 2 University of Michigan School of Public Health * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Krzysztof%2BSakrejda%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sakrejda%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKrzysztof%2BSakrejda%2B) * [ORCID record for Krzysztof Sakrejda](http://orcid.org/0000-0001-7587-355X "Open in new tab") Abram Wagner 2 University of Michigan School of Public Health * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abram%2BWagner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wagner%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAbram%2BWagner%2B) * [ORCID record for Abram Wagner](http://orcid.org/0000-0003-4691-7802 "Open in new tab") Jon Zelner 2 University of Michigan School of Public Health * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jon%2BZelner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zelner%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJon%2BZelner%2B) * [ORCID record for Jon Zelner](http://orcid.org/0000-0002-0708-2008 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1295219/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1295219/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1295219/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1295219/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1295219/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Difficulties ascertaining the true burden of infection and mortality from SARS-CoV-2 hindered disease surveillance and healthcare resource allocation throughout the COVID-19 pandemic. Although all-cause excess mortality estimates have long been deployed to avoid the challenges of case detection when testing availability is variable, aggregation of mortality by cause of death and spatial unit may mask underlying patterns and hide underlying associations with social factors. Furthermore, some noinfectious causes of death may have decreased during the pandemic, resulting in all-cause excess mortality capturing a net pandemic effect rather than the direct burden of Covid-19. Using mortality data in the state of Michigan from January 2015 - November 2019, we calculated the expected mortality for December 2019 - November 2022 using negative binomial regression. Comparing these estimates to the observed mortality, we calculated the burden of excess mortality during the winter 2019 influenza season and COVID-19 pandemic, as divided into 7 distinct periods based on dominant viral strains and pharmaceutical and non-pharmaceutical interventions implemented. All analyses were performed with the data aggregated by cause of death and to the county level and repeated at both the county and census tract level disaggregated into two crude cause of death categories: acute respiratory infections (ARIs) and all other causes (non-acute respiratory infections, non-ARIs). We examined spatial heterogeneity of excess mortality by cause using the Theil index to determine if variation in excess mortality was driven by differences between or within counties. The excess mortality rate from ARI peaked in the first phase of the pandemic, with a ratio of 10.7 observed to expected deaths (95% CrI: 10.3 -1.1). However, the all- cause excess mortality rate rose only to 1.20 excess deaths per expected (95% CrI: 1.17 - 1.22) and the non-ARI excess mortality rate was unchanged. Comparing ARI excess mortality rates calculated at the county vs. census tract level demonstrated large and unpredictable variation, with county level estimates ranging from 0.42 to 1.2 times the tract level estimates. However, county level estimates of non-ARI and all- cause excess mortality ratios were consistently closer to tract level estimates. Within county variation of ARI mortality decreased during the pandemic and slowly returned to reference levels, suggesting spatial patterning of ARI mortality became more similar across census tracts as rates rose statewide. Social vulnerability was associated with an increased ARI excess mortality rate ratio at the census tract level during the first pandemic phase (EMRR: 1.1, 95% CrI: 1.08 - 1.13), but this effect was attenuated when aggregated to all-cause mortality or to the county level. Our findings indicate that using county-level all-cause excess mortality as a proxy for ARI excess mortality obscuredthe burden of ARI death, particularly during the most acute phases of the COVID-19 pandemic. Relying on aggregated metric of all-cause mortality limits the power to detect large shifts in cause-specific mortality, and that limitation can be mitigated by even using coarse categories such as ARI vs. non-ARI deaths. Similarly, finer scale spatial units allow for the detection of local trends necessary to identify associated social factors. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The IRB of the University of Michigan gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data can be requested from the Michigan Department of Health and Human Services ## Funder Information Declared National Institutes of Minority Health and Health Disparities, R01MD017218 Simons Foundation, https://ror.org/01cmst727, 812255 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.04.26362027v1 "Coronary revascularisation in people with multiple long-term conditions: a systematic review and meta-analysis")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.04.26362306v1 "Red blood cell distribution width is an indicator of physiological dysregulation and reveals the relationship between biomarkers and health status in hemodialysis patients") Posted September 08, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/08/2026.09.04.26362260.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/08/2026.09.04.26362260.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Aggregation of mortality data by place and cause mask underlying trends in COVID-19 excess mortality Kelly Herdzik, Krzysztof Sakrejda, Abram Wagner, Jon Zelner medRxiv 2026.09.04.26362260; doi: https://doi.org/10.64898/2026.09.04.26362260 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.04.26362260v1%26text%3DAggregation%2520of%2520mortality%2520data%2520by%2520place%2520and%2520cause%2520mask%2520underlying%2520trends%2520in%2520COVID-19%2520excess%2520mortality "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.04.26362260v1%26t%3DAggregation%2520of%2520mortality%2520data%2520by%2520place%2520and%2520cause%2520mask%2520underlying%2520trends%2520in%2520COVID-19%2520excess%2520mortality "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.04.26362260v1%26title%3DAggregation%2520of%2520mortality%2520data%2520by%2520place%2520and%2520cause%2520mask%2520underlying%2520trends%2520in%2520COVID-19%2520excess%2520mortality%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.04.26362260v1%26title%3DAggregation%2520of%2520mortality%2520data%2520by%2520place%2520and%2520cause%2520mask%2520underlying%2520trends%2520in%2520COVID-19%2520excess%2520mortality "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.04.26362260) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.04.26362260v1&count=horizontal&via=&text=Aggregation%20of%20mortality%20data%20by%20place%20and%20cause%20mask%20underlying%20trends%20in%20COVID-19%20excess%20mortality&counturl=www.medrxiv.org/content/10.64898/2026.09.04.26362260v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (616) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (897) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (329) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4787) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (477) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (412) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (647) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1619) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15880) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1199) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7010) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (729) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1061) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5017) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1430) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1749) * [Hematology](https://www.medrxiv.org/collection/hematology) (583) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1340) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16265) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1166) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (666) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (721) * [Neurology](https://www.medrxiv.org/collection/neurology) (7222) * [Nursing](https://www.medrxiv.org/collection/nursing) (366) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1074) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1234) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1002) * [Oncology](https://www.medrxiv.org/collection/oncology) (3588) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1045) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (396) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (449) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (466) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (705) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1786) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (760) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5855) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9725) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2400) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1440) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1246) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (637) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (769) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (577) * [Surgery](https://www.medrxiv.org/collection/surgery) (774) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (303) * [Urology](https://www.medrxiv.org/collection/urology) (289) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid dupl
## Related Clinical Research

- [Hypothesis: Airborne Transmission of COVID-19 from Asymptomatic Individuals by Speaking](https://medichelpline.com/clinical-feed/pubmed-41320299.md) (DOI: 10.7883/yoken.JJID.2025.169)
- [Macrolide-Resistant Bordetella pertussis Detected in Peru During 2025 Outbreak](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-2-emergence-of-macrolide-resistant-bordetella-pertussis-peru-2025.md)
- [Pennsylvania reports third measles-related death amid ongoing outbreak; other health headlines](https://medichelpline.com/clinical-feed/stat-news-2-pennsylvania-records-third-measles-related-death-amid-outbreak.md)
- [SARS-CoV-2 variant resolution in Oregon wastewater using Freyja (Feb 2021–Feb 2022)](https://medichelpline.com/clinical-feed/plos-one-19-correlation-assessment-of-sars-cov-2-variants-and-their-subvariants-present-in.md)
- [Factors Associated with Influenza Vaccine Uptake Among Georgian Healthcare Workers, 2021–2024](https://medichelpline.com/clinical-feed/plos-one-23-factors-associated-with-influenza-vaccine-uptake-among-healthcare-workers-in.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.